HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Andere talen Hansoh Pharmaceutical Group Company Limited Börse Stuttgart

Aandelen

3KY

KYG549581067

Beurs gesloten - Börse Stuttgart Andere beurzen 10:36:27 20-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,95 ^EUR	-4,41%		0,00%	+19,30%

14/06	Hansoh Pharmaceutical verlaagt de conversieprijs van converteerbare obligaties	MT
29/04	Hansoh Pharmaceutical Group Company Limited kondigt wijzigingen aan in de leiding, met ingang van 29 april 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Hansoh Pharmaceutical Slashes Conversion Price of Convertible Bonds	14/06
Hansoh Pharmaceutical’s 2023 Profit Up 27%	30/04
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024	29/04
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug	03/04
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer	03/04
Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend, Payable on July 17, 2024	26/03
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules	08/02
Hansoh Pharmaceutical Buys Back 3 Million Shares	31/01
Fed, China Property Outlooks Roil Asian Stock Markets	30/01
2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	24/01
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug	23/01
China Outlook, Tech Rally Roils Asian Stock Markets	19/01
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment	17/01
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets	17/01
Federal Reserve Outlook Mutes Asian Stock Markets	05/01
Hansoh Pharmaceutical’s Trustee Buys Back Shares	02/01
GSK plc Enters Exclusive License Agreement with Hansoh for HS-20093	20/12
GSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer Antibody	20/12
Hansoh Pharmaceutical Grants GSK Subsidiary Marketing License for Tumor Drug HS-20093	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hansoh Pharmaceutical Group Company Limited Börse Stuttgart

Aandelen

3KY

KYG549581067

Andere talen

Filters